> CVE-2026-63265

« BACK_TO_HOME
PUBLISHED
2026-07-22 21:18
MODIFIED
2026-07-22 21:18
EPSS (Prob. Exploit)
0.18%
Top 92.8%
DATA SOURCES:
NVD 🔗 2026-07-22 CWE MITRE 🔗 2026-11-01 FIRST EPSS 🔗 2026-11-01

> DESCRIPTION

Privileged Regular Labs AJAX endpoints did not consistently require valid CSRF tokens, matching component/item permissions and trusted server-generated form configuration. Authenticated lower-privileged users or CSRF attacks could invoke lookups or mutations outside their authorization.

> AFFECTED_PRODUCTS

ℹ️ Aucun produit affecté n'a encore été publié par NVD pour cette CVE.

> WEAKNESSES

CWE-284 CWE-352

> CWE DETAILED DESCRIPTIONS

CWE-284: Improper Access Control - The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor. | CWE-352: Cross-Site Request Forgery - The web application does not, or cannot, sufficiently verify whether a request was intentionally provided by the user who sent the request, which could have originated from an unauthorized actor.

> HISTORIQUE DES MODIFICATIONS

Première apparition
22/07/2026 21:18
Source: NVD
📊 ENRICHISSEMENT 01/11/2026 06:59
CWE
Champ modifié: Description CWE
Ancienne valeur:
CWE-284: Improper Access Control - The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor. | CWE-352: Cross-Site Request Forgery (CSRF) - The web applic...
Nouvelle valeur:
CWE-284: Improper Access Control - The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor. | CWE-352: Cross-Site Request Forgery - The web application d...
📊 ENRICHISSEMENT 01/08/2026 06:01
CWE
Champ modifié: Description CWE
Ancienne valeur:
N/A
Nouvelle valeur:
CWE-284: Improper Access Control - The product does not restrict or incorrectly restricts access to a resource from an unauthorized actor. | CWE-352: Cross-Site Request Forgery (CSRF) - The web applic...
Total des modifications: 2 Dernière mise à jour: 5 days ago

> REFERENCES

https://regularlabs.com/
« BACK_TO_HOME